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Summary
Hereditary angioedema is a rare and disabling disease characterized by 
severe, acute, self- limiting edema of the subcutaneous and mucosal 
tissue. The disease carries significant mortality when the upper airways 
are involved. It is determined by a transient dysregulation in vascular 
permeability with a sudden increase in fluid extravasation. The most 
common genetic defects recognized on the SERPING1 gene leads to 
complement C1-inhibitor deficiency (C1-INH-HAE). In the last few years 
mutation on the factor XII gene, the angiopoietin, and the plasmino-
gen genes were recognized to cause angioedema with normal C1-INH 
levels (nC1-INH-HAE). However, it is not uncommon to have family hi-
story of angioedema and unknown genetic defect. The burden of the 
disease on the individual patients is unpredictable since the number, 
location and severity of the attacks spans from silent disease to an 
extremely high number of attacks during lifetime. Nowadays effective 
and safe treatment for the C1-INH-HAE forms are available and new 
drugs are under investigation both for the on demand therapy and for 
the prophylaxis of the attacks. Acute treatments has been proved to re-
duce severity and duration of attack, prophylaxis reduces the number 
of attacks thus positively affecting the quality of life and reducing the 
indirect costs of the disease. Unfortunately, the costs of the medica-
tions are high limiting the accessibility and availability of treatment in 
different countries. This paper reviews the treatment options and the 
differences in the availability of the medications in three European co-
untries, with practical suggestions for the management of the disease.
Keywords: hereditary angioedema, treatment, prophylaxis, C1 inhibitor, 
bradykinin receptor antagonist, kallikrein inhibitors
Streszczenie
Wrodzony obrzęk naczynioruchowy jest rzadką, upośledzającą funk-
cjonowanie chorobą chrakteryzującą się ciężkimi, ostrymi, samo-
ograniczającymi się obrzękami tkanki podskórnej i podśluzówkowej. 
W przypadku zajęcia górnych dróg oddechowych, schorzenie obar-
czona jest znaczącą śmiertelnością. Choroba jest determinowana 
przejściową dysregulacją przepuszczalności naczyniowej ze nagłym 
wzrostem ilości wynaczynionego płynu. Najczęściej spotykane defekty 
genetyczne występujące w genie SERPING1 prowadzą do niedoboru 
inhibitora składowej C1 układu dopełniacza (C1-INH-HAE). W ostat-
nich kilku latach poznano mutację genów czynnika XII, angiopoetyny 
i plazminogenu powodujące obrzęk naczynioruchowy z prawidłowym 
poziomem C1-INH (HAEnC1-INH). Jednakże, nie jest sytuacją niezwykłą 
występowanie rodzinnego wywiadu w kierunku obrzęku przy niezna-
nym defekcie genetycznym. Obciążenia związane z chorobą u poszcze-
gólnych pacjentów są trudne do przewidzenia, ponieważ liczba, lokali-
zacja i ciężkość napadów w ciągu życia zmienia się: od okresów remisji, 
do okresów ze skrajnie częstymi objawami. Obecnie dostępne są sku-
teczne i bezpieczne formy leczenia C1-INH-HAE, a w trakcie badań są 
nowe leki, zarówno do doraźnej, jaki i profilaktycznej terapii napadów 
obrzęku. Leki stosowane w stanach ostrych mają potwierdzone dzia-
łanie zmniejszające ciężkość i czas trwania napadów, a leki stosowane 
w profilaktyce zmniejszają częstość napadów wpływając pozytywnie 
na jakość życia i redukując pośrednie koszty choroby. Niestety kosz-
ty leczenia są wysokie i ograniczają jego dostępność w wielu krajach. 
W niniejszej pracy dokonano przeglądu możliwych opcji terapeutycz-
nych i ich dostępności w trzech krajach europejskich, poszerzonego 
o praktyczne sugestie dotyczące leczenia choroby. 
Słowa kluczowe: wrodzony obrzęk naczynioruchowy, leczenie, 
profilaktyka, C1-inhibitor, antagoniści receptora bradykininowego, 
inhibitory kalikreiny
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INTRODUCTION
Hereditary angioedema (HAE) is a disease characterized 
by recurrent self-limiting episodes of oedema without ur-
ticaria localized at the extremities, face, genitals, gastroin-
testinal and upper airway mucosa. Laryngeal involvement 
may cause fatal asphyxiation. HAE prevalence is uncertain, 
with estimates ranging between 1 in 10 000 and 1 in 150 
000 persons worldwide [1-5]. It is most commonly due to 
genetic complement C1-inhibitor deficiency (C1-INH-HAE) 
even if, recently, other new mutations on different genes 
have been recognized [6-8].
In the pathophysiology of the acute attacks C1-INH plays 
a central role in the control of the activity of contact system 
enzymes, factor XIIa and plasma kallikrein. C1-INH deficien-
cy facilitates contact system activation and local release of 
the vasoactive peptide bradykinin, responsible for oedema 
formation [9]. There are several types of HAE (Fig. 1). Two 
forms of the disorder arise from deficiency or dysfunction 
of C1-INH (types I and II, respectively), and can be detect-
ed by abnormal complement protein levels [10]. The other 
types of familial angioedema are characterised by normal 
C1-INH (nC1-INH-HAE) and normal complement studies. 
A small but growing number of suspected pathogenic var-
iants in genes addressed to other protein synthesis have 
been identified to explain the disease in some families. In 
2006 the first associated coagulation factor XII mutation 
was identified [6], and in 2018 the angiopoietin-1 and plas-
minogen genes were discovered [7, 8]. The pathogenesis in 
other families with unidentified gene mutation nowadays 
remains unclear. C1-INH-HAE depends on heterozygous 
SERPING1 variants that cause deficient production of the 
protein. Its immunological diagnosis is based on antigen-
ic and/or functional plasma C1-INH levels below 50% of 
normal. The clinical penetrance of this defect approaches 
100%, and angioedema stands out clearly in affected sub-
jects.
BODY OF THE ARTICLE
Frequency and severity of angioedema recurrences are 
highly variable and represent the main drivers of disease 
burden. Different choices in the management of therapies 
should be considered according to the number and severity 
of the attacks, the impact on quality of life, and the avail-
ability of the treatment that is different in different coun-
tries. The treatment efficacy is different being dependent 
on the underlying hereditary defect. There is not a complete 
agreement concerning the on demand treatment (ODT) 
versus prophylactic treatment (PT) therapeutic strategies. 
While drugs that are effective on demand represent the 
solely approach to avoid mortality related to life-threaten-
ing attacks, both ODT and PT can reduce disease burden 
reducing severity and duration of attacks. PT has the addi-
tional advantage on reducing also attack frequency. Thus, 
complementary use of ODT and PT should be addressed 
from clinical standpoint and also for economics consider-
ations. Indeed, the impact of direct and indirect costs on 
the society is relevant, the recurrences of the attacks cause 
significant disability with a consistent humanistic and eco-
nomic impact of the disease due to reduced performances 
at school or work for patients and their caregivers [11-14].
Healthcare payers and healthcare systems worldwide 
raise major concerns about the financial impact of the al-
ready available and newly approved therapies on health-
care payment systems. The amount of the expenses leads 
to barriers and limitation of access to these life changing/
saving therapies. This review will describe the differences 
of availability and access to therapies for the ODT and PT in 
Poland, Bulgaria and Italy, as an example for future consid-
eration and development of sustainable and fair treatment 
policy of this rare disease.
Fig. 1. Classification of the different form of hereditary angioedema
Legend: HAE - hereditary angioedema; C1-INH - C1 inhibitor; FXII - factor twelve; ANGPT1 - angiopoietin-1; PLG - plasminogen
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Diagnosis: practical suggestions
In synthesis, the diagnosis of HAE should be considered 
in patients who demonstrate recurrent self-limited episodes 
of angioedema without urticaria or pruritus, lasting for two 
to five days (without treatment); when colicky, abdominal 
pain are recurrent and unexplained; when even a single la-
ryngeal edema attack occurs, and when other known ac-
quired forms of angioedema are excluded according to the 
consensus report from the Hereditary Angioedema Interna-
tional Working Group [10]. The presence of a positive fam-
ily history of angioedema is suggestive but in some cases is 
absent. The type of angioedema is assessed by C1-INH and 
C4 measurements.
Treatment strategies in HAE
Acute treatment reduces severity and duration of at-
tack for most patients, whose quality of life has improved 
since such treatments became available [15]. C1 inhibitor 
(plasma-derived or recombinant), ecallantide, or icatibant 
are effective acute treatments (details and table in the next 
chapter).
However, the assessment and protection of the upper 
airway is the first and most important management issue 
in the patient presenting with an acute attack involving any 
part of the airways, as none of the available therapies is uni-
versally effective. The maintenance of the airway patency 
must be carefully and promptly evaluated and maintained 
since the efficacy of the action of these agents requires 
time.
Every patient should have an acute care plan, the best 
acute treatment should be decided on an individual basis 
considering the specific environment of the patient, his/
her compliance and possibility of self-administration and 
the presence of a care-giver. Best acute treatment may vary 
between attacks and should be re-evaluated over time for 
a given patient since the recurrence and severity of the at-
tacks is likely to be different during the whole life.
Acute treatment of attacks in C1-INH-HAE
Acute treatment of hereditary angioedema due to C1 
inhibitor deficiency has become available in the last 10 
years and has greatly improved patients’ quality of life. Two 
plasma-derived C1 inhibitors (Berinert® and Cinryze®), 
a recombinant C1 inhibitor (Conestat alpha/ Ruconest®), 
a kallikrein inhibitor (Ecallantide/Kalbitor®), and a brady-
kinin B2 receptor antagonist (Icatibant/Firazyr®) are all ef-
fective [16-21]. The relative efficacy of the drugs has not 
been compared in head-to-head trials. Sustainable good re-
sponse is maintained over repeated treatments and several 
years. All currently available prophylactic agents are associ-
ated with breakthrough attacks; therefore, an acute treat-
ment plan is essential for every patient, irrespectively to the 
presence of PT. The efficacy of human plasma in treating 
acute attacks has been suggested by case reports. No con-
trolled trials have been ever performed [22].
In Italy, two plasma derived and one recombinant C1-
INH (Berinert®, Cinryze®, Ruconest®), and the bradykinin 
receptor antagonist icatibant (Firazyr®) are registered for 
ODT. However, Ruconest is not always reimbursed by the 
Italian National Healthcare System, and its use remains 
marginal. Icatibant is delivered as prefilled syringe to be ad-
ministered subcutaneously at a fixed dose of 30 mg, where-
as plasma-derived C1-INH (pdC1-INH) is delivered in vials 
of 500 IU for a weight-based dose of 20 IU/Kg. In Poland 
authorized and reimbursed treatment for ODT are recom-
binant C1-INH, plasma derived C1-INH and icatibant, while 
in Bulgaria only plasma derived and recombinant C1-INH 
are available (Table III). The use of ecallantide is approved 
by the Food and Drug Administration, only in the US. For 
children and pregnant women, plasma-derived C1 inhibitor 
has the best evidence for safety and currently remains first-
line treatment.
The main characteristics of HAE medications are summa-
rized in Table I.
Other new small molecules are under investigation for 
future use in the acute and prophylactic treatment of the 
attacks. BCX7353 is a novel oral plasma kallikrein inhibitor 
with promising results (preliminary data from the ZENITH-1, 
trial-unpublished) [25] showing that a single 750 mg oral 
dose of BCX7353 was well tolerated and superior to place-
bo for the treatment of acute attacks in HAE patients.
Another treatment under investigation in a Phase I tri-
al for acute AE attacks modulates the inhibition of plasma 
kallikrein (PK). KVD 900 (KalVista) is a novel small molecule, 
selective and orally available PK inhibitor that is protective 
against PK-mediated high molecular weight kininogen (HK) 
cleavage in undiluted HAE and control plasma in an ex vivo 
assay [26].
Prophylaxis of C1-INH-HAE
The clinical considerations for long-term prophylaxis 
(LTP) therapy of C1-INH-HAE have significantly changed in 
recent years from pre-defined criteria of numbers of attacks 
or days of disability, to an individualized approach, taking 
multiple factors into account [27]. The contemporary state 
of mind is that C1-INH-HAE is a multi-factorial condition 
that affects each patient’s life differently and with various 
burden even in the same patient over time [28].
Disease severity should be evaluated in the context of im-
pact on quality of life and ability to conduct daily activities, 
and/or leisure [29]. Attack numbers, days of disability, or 
hospitalizations are controversial and might not necessarily 
be best indicative for the impact of the disease over the 
individual patient [30]. The first effective prophylactic drugs 
were oral androgens. Efficacy was found almost serendipity 
in 1960 before C1-INH deficiency was known to underlying 
HAE [31]. Ten years later, in absence of strong pathophysi-
ologic rationale, antifibrinolytic agents were started in HAE 
prophylaxis. Efficacy has never clearly been proved and their 
use remained marginal. Thus, for 40 years, attenuated an-
drogens remained the milestone of HAE prophylaxis. Their 
easy availability and low cost allowed patients around the 
world to access this treatment. Need for alternative comes 
from obvious side effects of such an approach. During that 
time, the first studies of intravenous plasma-derived C1-INH 
(pdC1-INH) for acute attacks showed promising clinical out-
comes, with proper dose-selection being among the main 
unknowns. Viral-safety at that time was to be substantially 
improved overtime, yet with historical insecurity in patients 
and physicians with the early formulations [32-34]. Since 
then, the first studies with intravenous pdC1-INH for long-
term prophylaxis provided evidence for the efficacy, safety
 
and effect on quality of life,
 
and many patients have ben-
efited from this therapy. Nowadays, viral safety of C1-INH 
178 Alergia Astma Immunologia 2018, 23 (4): 175-185
Drug 
(molecule), 
Route of 
administration
Commercial 
name
Subjects and 
therapeutic regimen 
for prophylaxis
Adverse events Warnings and precautions References
pdC1-INH, 
I.V.
Berinert 
500 and 
1500 IU, 
CSL Behring
Adults, adolescents, 
and children; 
20 IU/kg 
I.V.
Headache, nausea, 
rash, vomiting and 
fever
Theoretical infectious 
agents’ transmission. 
Thrombotic and 
thromboembolic 
events. 
Allergic reactions. 
Potential 
immunogenicity.
[15-17]
pdC1-INH, 
I.V.
Cinryze, 
Shire
Adults and adolescents; 
1000 IU, 
I.V. (additional 1000 
U at discretion of 
physician)
Headache, nausea, 
rash, vomiting and 
fever
Theoretical infectious 
agents’ transmission. 
Thrombotic and 
thromboembolic 
events. 
Allergic reactions. 
Potential 
immunogenicity.
[23]
rhC1-INH 
Conestat alfa 
I.V.
Ruconest 
Pharming
Adults and adolescents; 
50 IU/kg up to 4200 U 
(if ≥ 84 Kg) 
S.C.
Headache, nausea, 
diarrhea, sneezing, 
skin burning 
sensation or rash, 
back pain, changes 
in taste, and 
spinning sensation 
(vertigo)
Allergic 
hypersensitivity 
reactions.
[20]
Bradykinin 
B2 receptor 
antagonist 
Icatibant 
S.C.
Firazyr 
Shire
Pre-filled syringe 
30 mg prefilled 
S.C.
Local injection site 
reactions
Avoid in acute 
thrombosis. [19]
Ecallantide 
Kallikrein 
antagonist 
S.C.
Kalbitor 
Dyax Corp.
Vial 10 mg 
30 mg (3 mL) S.C. 
administered in 3 
separate 10 mg (1 mL) 
injections; 
Allowed an additional 
dose of 30 mg within 
24 hours
>10% headache, 
nausea, fatigue, 
diarrhea
Self-administration 
not allowed. 
Anaphylactoid events.
[21]
Oral molecule 
targeting 
plasma 
kallikrein #, 
P.O.
BCX7353, 
Avorlastat, 
Biocryst
Adults 
750 mg 
P.O.
Gastrointestinal 
events (nausea, 
vomiting, diarrhea, 
abdominal pain), 
skin rash, elevated 
liver enzymes, 
fatigue, headache, 
nasopharyngitis.
Higher doses 
associated with 
higher frequency of 
gastrointestinal AEs. 
Theoretical precaution 
for cardiovascular 
accidents. 
Expected drug 
interactions with 
medications 
interfering with CYP2 
family.
[24]
# exploratory trial, results expected in the first quarter of 2019
pdC1-INH: plasma derived C1 inhibitor; rhC1-INH: recombinant human C1 inhibitor; Bradykinin B2 receptor: bradykinin beta two receptor; 
I.V.: intra venous route; S.C.: subcutaneous; P.O.: oral route of administration
Table I. HAE-specific treatment for treatment of acute attacks
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products is nearly fully secured by means of modern bio-
technologies and strict monitoring production processes 
[35].
However, there is a treatment burden associated with 
any intravenously administered medication. Often, patients 
are unable or unwilling to access their veins for drug admin-
istration. Patients with venous access problems used subcu-
taneous ports, which are associated with risks of infection 
and thrombosis [36, 37]. Recently, new prophylactic thera-
pies have improved efficacy, a more favourable benefit-risk 
profile, and a reduced treatment burden aiming to change 
the considerations for prophylaxis therapy among patients 
and physicians [38, 39]. Subcutaneous therapies avoid the 
need for venous access and likely reduce the treatment bur-
den compared to intravenous administration. Development 
of a safe and effective oral therapy would meet the major 
unmet need by terms of ease of treatment administration. 
With these improvements in therapeutic options, prophy-
laxis therapy will likely start to be used more often in HAE 
patients, leading to individual patient-tailored treatment to 
diminish disease burden.
A promising and completely different approach to pro-
vide long-term protection from angioedema attacks in af-
fected individuals is under investigation in a C1 Heterozy-
gote C1-INH deficient mouse model. A single treatment 
intravenous administration of an adeno-associated virus 
(AAV) gene transfer vector expressing the genetic sequence 
of the normal human C1 esterase-inhibitor (AAVrh.10hC1EI) 
is effective in providing sustained circulating C1-INH levels 
sufficient to prevent angioedema episodes [40]. At present 
the program of using this vector in HAE is on hold since 
most recent data form the study in alpha1 anti-thrypsin 
failed to observe a clinically meaningful level of protein ex-
pression [41].
Patients with HAE with normal C1-INH tend not to re-
spond to epinephrine, antihistamines, or glucocorticoids, 
similar to those with C1-INH-HAE. However, in absence of 
knowledge on this heterogeneous condition these thera-
pies remain first choice approach until inefficacy is clearly 
assessed.
Treatment options for HAE with normal C1-INH are not 
defined. It is assumed that their pathogenesis goes through 
kallikrein mediated release of bradykinin. Based on this as-
sumption bradykinin targeted approach as for C1-INH-HAE 
has been attempted. However, treatment experience is lim-
ited and results anecdotal in absence of controlled clinical 
trials. Several novel field of investigation to reduce produc-
tion of bradykinin are in the preclinical phase such as 2 RNA 
interference drugs affecting factor XII production, ALNF12 
and ARC-F12; a monoclonal antibody antifactor XIIa, CSL 
312; and gene therapy.
The drugs currently used for LTP of C1-INH-HAE are sum-
marized in Table II.
Treatment availability in Poland, Bulgaria and Italy
Treatment availability in Italy, Poland and Bulgaria are 
summarized in the Table III.
Italy
The story of HAE in Italy began in 1971 when the first 
C1-INH-HAE patient was diagnosed. For the diagnosis Pro-
fessor Angelo Agostoni sent a sample of serum to Virgin-
ia Donaldson, who showed the lack of C1-INH antigen by 
immune-electroforetic technique using an anti-C1-INH spe-
cific antiserum. By that time, therapy was limited to some 
initial experience with fresh frozen plasma to reverse acute 
attacks. For the same purpose the Italian group used with 
some success the anti-proteasic compound Trasylol [55]. In-
terestingly, Trasylol was made of aprotinin extracted from 
bovine lungs. The aminoacid sequence of the reactive site 
of aprotinin was used derive ecallantide, the recombinant 
anti kallikrein registered in U.S. for on demand treatment of 
HAE. By 1974 two additional families had been diagnosed 
in Milan and at the Netherland Red Cross (now Sanquin) 
the first C1-INH concentrate from plasma had been pre-
pared for human use [56]. Dr Brummelhuis made available 
samples of this preparation to Prof. Agostoni, who used 
it in two HAE patients at two different doses (12,000 and 
36,000 U) to reach significant post infusion increase of the 
deficient protein (Marco Cicardi, Doctorate thesis 1975). 
In the same time other companies engaged in plasma de-
rived product (Immuno Vienna, Berhing Marburg and the 
American Red Cross) worked on C1-INH preparations that 
reached the European market around 1985. In U.S. devel-
opment of new plasma products was stopped when the HIV 
epidemic became apparent. The C1-INH preparation that 
just started to be tested was placed on hold and until 2008 
no plasma derived C1-INH has been registered in U.S. [57].
Since 1983, Immuno’s C1-INH was the first marketed 
preparation to become generally available for treatment of 
severe acute HAE attacks for Italian C1-INH-HAE patients. 
In 1976 the group of Frank provided clear evidence for the 
capacity of the attenuated androgen danazol, not only to 
dramatically reduce angioedema attacks, but also to revert 
C1-INH deficiency in HAE patient. For 35 years plasma de-
rived C1-INH as ODT and danazol as PT covered the thera-
peutic needs of Italian HAE patients. Year 2010 represents 
the start of the new era of the HAE treatment that now sees 
two plasma derived C1-INH, one recombinant C1-INH, one 
bradykinin B2 receptor antagonist, one inhibitor of plasma 
kallikrein and one recombinant monoclonal antibody tar-
geting plasma kallikrein available for OD and/or LTP.
Poland
The first Polish family with members affected by C1-INH-
HAE was reported by Dr. Korzeniewska at a local allergists’ 
session in 1984. A year after, Prof. Krystyna Obtulowicz di-
agnosed in Krakow the next patient with a severe, and life 
threating clinical course of the disease. In response to the 
request of Prof. Obtulowicz’s, Berhing company donated 
a certain amount of human plasma derived C1-INH to the 
hospital in Krakow. This “stock” served as a rescue treat-
ment for quite a long time for that exact patient, who still 
remains under care in the same center, as well as for other 
newly diagnosed in the meantime patients [58]. Unfortu-
nately, except the situation described above, the early be-
ginnings of HAE management in Poland were much more 
difficult. The only licensed drug, Berinert, could be obtained 
by means of direct import for a particular patient. This pro-
cedure was challenging and long-lasting, therefore a real 
access to rescue treatment was very limited. Over the years, 
attenuated androgens (mostly danazol) were widely uti-
lized, both for long-term prophylaxis and for HAE attacks, 
despite of many reported side effects. Children and preg-
nant women were treated with the anti-fibrinolytic agent - 
tranexamid acid, which is inexpensive and widely available, 
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Drug 
(molecule), 
Route of 
administration
Commercial 
name
Subjects and 
therapeutic 
regimen for 
prophylaxis
Adverse events Warnings and precautions References
Androgens, 
P.O. Danazol
Adults, 
Lowest 
therapeutically 
relevant dose 
(50-200 mg/d 
P.O.) 
Hepatotoxicity, 
virilization, 
hepatocellular 
carcinoma, lipid 
abnormalities, 
weight gain, 
mood effects
Preferably not to use in 
females and pre-puberty 
children. 
Potential virilization of the 
fetus. 
Dose more than 200 mg/d 
not advised for LTP use. 
Do not use in subjects with 
malignant tumors (breast 
and prostate cancer). 
[42-46]
Tranexamic 
acid, 
P.O.
Tranex
Adults and 
adolescents 
500-3000 
mg/d P.O.
Diarrhoea, 
nausea, vomiting, 
pruritus, 
headache, 
myalgia
No plain efficacy proofs. 
Beware of thrombotic 
complications in 
predisposed patients
[47, 48]
pdC1-INH, 
I.V.
Berinert ¥ 
500 and 1500 
IU,  
CSL Behring 
Adults, 
adolescents, 
and children; 
20 IU/kg, 
twice weekly, 
I.V.
Headache, 
nausea, rash, 
vomiting and 
fever
Theoretical infectious 
agents’ transmission. 
Thrombotic and 
thromboembolic events. 
Allergic reactions. 
Potential immunogenicity.
[49-52] 
SPC of the 
product
pdC1-INH, 
I.V.
Cinryze,  
Shire
Adults and 
adolescents; 
1000 IU, twice 
weekly, I.V. 
(up to 2500 
IU, but no 
more than 
100 IU/kg)
Headache, 
nausea, rash, 
vomiting and 
fever
Theoretical infectious 
agents’ transmission. 
Thrombotic and 
thromboembolic events. 
Allergic reactions. 
Potential immunogenicity.
[17, 32, 53, 
54] 
SPC of the 
product
Low-volume 
pdC1-INH*, 
S.C.
HAEGARDA, 
CSL Behring
Adults and 
adolescents; 
60 IU/kg, 
twice weekly, 
S.C.
Injection site 
reactions, 
hypersensitivity, 
nasopharyngitis, 
and dizziness
Theoretical infectious 
agents’ transmission. 
Potential thrombotic 
events. 
Potential tachyphylaxis.
[38] 
SPC of the 
product 
NCT01576523 
NCT01912456 
NCT02316353
Rh mAb 
targeting 
plasma 
kallikrein, 
S.C.
Lanadelimab * 
Shire
Adults and 
adolescents; 
300 mg, 
twice or once 
monthly, 
S.C.
Injection site 
reactions, 
hypersensitivity, 
nasopharyngitis, 
rash, and 
dizziness
Potential immunogenicity. 
Theoretical precaution for 
cardiovascular accidents, 
bleeding, and autoimmune 
disorders.
[39] 
SPC of the 
product 
NCT02586805
Oral molecule 
targeting 
plasma 
kallikrein, 
P.O.
BCX7353 # 
Avorlastat, 
Biocryst
Adults 
110-150 mg 
daily P.O.
Gastrointestinal 
events (nausea, 
vomiting, 
diarrhea, 
abdominal 
pain), skin rash, 
elevated liver 
enzymes, fatigue, 
headache, 
nasopharyngitis.
Higher dose associated 
with higher frequency of 
gastrointestinal AEs. 
Theoretical precaution for 
cardiovascular accidents. 
Expected drug interactions 
with medications 
interfering with CYP2 
family.
[24]
* - under registration process in Europe
# - under phase III investigation
¥ - not registered for LTP but historically and often used in clinical practice
Table II. HAE-specific treatments for prophylaxis of attacks
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Drug
Italy  Poland  Bulgaria   
OD
pdC1-INH Berinert® 500 Yes Yes Yes
pdC1-INH Berinert® 1500 Yes Yes Not available
pdC1-INH Cinryze® Yes Not available Not available
rhC1-INH Ruconest® Yes (# not all regions) Yes Yes
Icatibant Firazyr® Yes Yes No (expected in 2019)
Ecallantide Kalbitor® Not available Not available Not available
STP
C1-INH iv Yes Yes Yes
Androgens Yes # off-label and not reimbursed Not available
LTP
Tranexamic acid Yes # off-label and not reimbursed Not available
Androgens Yes # off-label and not reimbursed Not available
C1-INH iv Yes # not reimbursed # off-label
scC1-INH Berinert Off-label # not reimbursed Not available
Lanadelumab* Yes Not available Not available
BCX7353* Yes Not available Not available
OD - on demand therapy; STP - short-term prophylaxis; LTP - long-term prophylaxis; pd - plasma-derived; rh - recombinant human; sc - 
subcutaneous; iv - intravenous
*clinical trials - extensions
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Table III. Treatment availability in Italy, Poland and Bulgaria
but far less effective than first-choice treatments. Due to 
shortages of Berinert, fresh frozen human plasma was the 
main therapy for most severe edema attacks in emergency 
situations.
These “early therapies” have been substituted gradu-
ally by disease-specific drugs, which received regulatory 
approval for C1-INH-HAE patients in the European Union, 
US, and other countries. In Poland, a major breakthrough 
in treatment of acute attacks took place between March 
2013 and June 2015. Within this period, the national public 
health authorities decided to reimburse the costs of on de-
mand treatment with Ruconest, followed by Berinert, and 
Firazyr. This made the drugs available for Polish C1-INH-HAE 
patients. Moreover, Berinert is also available for short-term 
prohylaxis. Training courses among patients for self-ad-
ministration were another important step towards better 
management of the disease. Drugs targeting the contact 
system cascade, such as aprotinin in the past or ecallantide 
at present, have never been used in Polish HAE patients. 
Other new molecules or technologies, which have been 
recently investigated, for instance lanadelumab targeting 
plasma kallikrein in order to prevent angioedema attacks, 
or shifting C1-INH delivery from intravenous to subcutane-
ous route for prophylaxis of attacks, wait to be introduced 
into everyday practice in Poland.
Bulgaria
The first C1-INH-HAE family in Bulgaria was diagnosed 
in 1972 by Prof. Bozhko Bozhkov who sent serum samples 
for complement investigations to Prof. Sir Peter Lachmann 
in the UK [59]. More families were recognized in the fol-
lowing years in the Clinic of Allergy in Sofia. Still, there was 
a long period of “dark ages” by terms of treatment availa-
bility and disease awareness for patients in Bulgaria. In the 
beginning, fresh frozen human plasma (FFP) was the only 
available (in theory) treatment for acute attacks. Neverthe-
less, this was an option considered only in medical facili-
ties where physicians were aware about the diagnosis (1-2 
centers throughout the country).
After 1990, attenuated androgens began to be used for 
treatment of the disease, with a price not affordable for 
patients, and a possible state reimbursement after a bulky 
protocol procedure only for selected cases of very severe 
course of the disease. “Lucky” patients only received the 
drug for several years until in 1998 the drug definitively dis-
appeared from the pharmaceutical market of the country. 
This caused an unresolved problem also for other patients 
with indication to receive continuous androgen therapy 
(e.g. endometriosis).
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For a very short period Trasylol was available for acute 
HAE attacks but treated cases were less than 2% of all C1-
INH-HAE patients. The risk and fear for acute anaphylactic 
reactions actually expelled the drug from use, consistent 
with its faith in other countries.
During the years 2000-2012, patients were followed 
with the only possibility to advise the severe cases seek 
prophylaxis options in fitness websites where vague stanoz-
olol-containing aimed for body-building food supplements 
were marketed online. FFP remained the only possibility for 
acute HAE attacks, again with very low percentage of the 
attacks being actually treated.
Many HAE patients were forced to seek better healthcare 
conditions, and decided to immigrate to other European 
Fig. 2. GDP and C1-INH availability
Fig. 3. GDP per capita (current US$) and C1-INH availability (source data.worldbank.org)
Legend: GDP - gross domestic product;
Italy: C1-INH first injected in 1974; C1-INH generally available since 1983;
Poland: Rh Ruconest since 2013, pd Berinert 500 since 2014, icatibant since 2015;
Bulgaria: C1-INH (rh Ruconest and pd Berinert 500 registered in 2013 and reimbursed since 2014)
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accomplished (rhC1-INH, Ruconest, and thereafter, pdC1-
INH, Berinert 500), and started to be reimbursed during 
2014. The drugs are indicated for acute episodes of HAE 
with no limit of localization, or severity of the attacks. Lives 
of C1-INH-HAE patients gradually improved with less hours 
with angioedema, better quality of life, and ameliorated 
possibility to maintain working and leisure activities. Future 
improvement would come when various treatment options 
by terms of route of administration, as well as, option for 
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Healthcare and economic specificities of HAE 
and future perspectives 
In the last decade, the development of new, disease-spe-
cific therapies to treat HAE has revolutionized patient man-
agement. However, the cost of these treatments remains 
high and availability differs by country and region [60, 61]. 
The development of new specific drugs for treatment of 
HAE was made possible by researchers and pharmaceutical 
industry and via the orphan drug policies now available in 
the European Union and the United States. Nevertheless, 
countries differ by terms of economic indicators and health-
care status, and this is also demonstrated by HAE medica-
tion availability in regions throughout the European Union, 
as well. For example, Western economies helped sustained 
drug development and disease investigation to bring avail-
able treatment possibilities for HAE patients worldwide. As 
exampled in Figure 2, the first injection of C1-INH concen-
trate extracted from human plasma for investigational pur-
poses was conducted in Italy back in the beginning of 1974. 
Since then, HAE treatment significantly changed, together 
with knowledge about the pathomechanisms attributing to 
the disease. Another example is HAE specific drug availa-
bility in Poland and Bulgaria (Figure 2 and 3): introduced 
approximately when the countries’ gross domestic product 
(GDP) and GDP per capita indicators became equal to that 
of Italy when HAE treatment was generally available back 
in 1983. Another point of view could be that HAE-specific 
treatments became generally available when rising C1-INH 
therapies started to be widely marketed in new regions 
around the world, as drug production could be sustainably 
maintained.
Finally, return of granted investments and bringing HAE 
treatments to a more affordable price by modern technolo-
gies would help distribute treatment options further in re-
gions where even nowadays the only life-saving option for 
C1-INH-HAE patients remains human plasma on demand.
COMMENTARY
Although, several new therapies for acute attacks of he-
reditary angioedema, and prophylaxis for patients with re-
current episodes have been introduced in the past decade, 
C1-INH-HAE remains a complex disease with a significant 
physical, psycho-social, and economic burden for both af-
fected patients, their families, and the society in general. 
Not all treatments are appropriate for all patients, neither 
is the availability secured throughout different regions of 
the world, nor even throughout different parts of Europe.
Research is ongoing to improve HAE diagnosis and se-
lection of individualized therapy for every patient in order 
to optimize clinical outcomes. Still, the disease has a seri-
ous economic impact with high direct and indirect costs, 
and high expenses related to the new therapies developed 
for patients to reduce symptoms and attack recurrence. As 
a result, treatment of HAE is often complicated by econom-
ic barriers and optimal management obstacles that must 
be overpassed to provide the best care for the patients with 
this rare disease.
KEY POINTS
• C1-INH-HAE is a multi-faceted disease that affects each 
patient’s life differently and with various burden even in 
the same patient over the time of his life.
• Specific HAE treatments are nowadays effective and safe 
to treat both acute angioedema manifestations, as well 
as, prevent recurrence of attacks.
• C1-INH-HAE remains a complex disease with a significant 
physical, psycho-social, and economic burden to both af-
fected patients, their families, and the society in general.
• Availability of HAE specific medications is not ubiqui-
tously distributed across-the-borders, neither through-
out European countries, nor worldwide. 
• Effective disease management is often complicated by 
economic barriers and optimal treatment obstacles that 
must be overpassed to provide the best care for the pa-
tients with this rare disease.
184 Alergia Astma Immunologia 2018, 23 (4): 175-185
  9. Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in 
hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 
193-204.
10. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and 
approach to treatment for angioedema: consensus report from 
the Hereditary Angioedema International Working Group. Allergy 
2014; 69: 602-16.
11. Aygoren-Pursun E, Bygum A, Beusterien K, et al. Socioeconomic 
burden of hereditary angioedema: results from the hereditary an-
gioedema burden of illness study in Europe. Orphanet J Rare Dis 
2014; 9: 99.
12. Banerji A, Busse P, Christiansen SC, et al. Current state of hereditary 
angioedema management: a patient survey. Allergy Asthma Proc 
2015; 36: 213-7.
13. Lumry WR. Hereditary Angioedema: The Economics of Treatment of 
an Orphan Disease. Front Med (Lausanne) 2018; 5: 22.
14. Federici C, Perego F, Borsoi L, et al. Costs and effects of on-demand 
treatment of hereditary angioedema in Italy: a prospective cohort 
study of 167 patients. BMJ Open 2018; 8: e022291.
15. Bork K, Bernstein JA, Machnig T, Craig TJ. Efficacy of Different Medi-
cal Therapies for the Treatment of Acute Laryngeal Attacks of Here-
ditary Angioedema due to C1-esterase Inhibitor Deficiency. J Emerg 
Med 2016; 50: 567-80 e1.
16. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 estera-
se inhibitor concentrate compared with placebo in acute hereditary 
angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8.
17. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor con-
centrate for treatment of hereditary angioedema. N Engl J Med 
2010; 363: 513-22.
18. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks 
in hereditary angioedema with a bradykinin receptor-2 antagonist 
(Icatibant). J Allergy Clin Immunol 2007; 119: 1497-503.
19. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-
-receptor antagonist, in hereditary angioedema. New Eng J Med 
2010; 363: 532-41.
20. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor 
for the treatment of acute angioedema attacks in patients with he-
reditary angioedema. J Allergy Clin Immunol 2010; 126: 821-7.e14.
21. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of 
acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 
523-31.
22. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the 
treatment of hereditary angioedema. Ann Allergy Asthma Immunol 
2007; 98: 383-8.
23. Lunn M, Santos C, Craig T. Cinryze as the first approved C1 inhibitor 
in the USA for the treatment of hereditary angioedema: approval, 
efficacy and safety. J Blood Med 2010; 1: 163-70.
24. Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral Pla-
sma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema. 
N Engl J Med 2018; 379: 352-62.
25. https://globenewswire.com/news-release/2018/09/04/1564738/0/
en/BioCryst-Reports-Positive-Results-Across-Multiple-Endpoints-in-
-ZENITH-1-Trial-of-Oral-BCX7353-as-Acute-Therapy-for-Hereditary-
-Angioedema-HAE-Attacks.html.
26. Feener EP, Murugesan N, Robson PA, et al. KVD900 protects high 
molecular weight kininogen (HK) from ex vivo plasma kallikrein me-
diated cleavage in plasma from patients with hereditary angioede-
ma (HAE): Results from a semi-automated capillary-based immuno-
assay. EAACI 2018, May 26-30 Munich.
27. Craig T, Busse P, Gower RG, et al. Long-term prophylaxis therapy in 
patients with hereditary angioedema with C1 inhibitor deficiency. 
Ann Allergy Asthma Immunol 2018; S1081-1206(18)30611-2.
28. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor defi-
ciency: biological and clinical characteristics in 235 patients. Medi-
cine (Baltimore) 1992; 71: 206-15.
29. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden 
of hereditary angioedema: Impact on health-related quality of life, 
productivity, and depression. Allergy Asthma Proc 2010; 31: 407-
14.
30. Bowen T. Hereditary angioedema: beyond international consensus 
- circa December 2010 - The Canadian Society of Allergy and Clini-
cal Immunology Dr. David McCourtie Lecture. Allergy Asthma Clin 
Immunol 2011; 7: 1.
31. Spaulding WB. Methyltestosterone therapy for hereditary episodic 
edema (hereditary angioneurotic edema). Ann Intern Med 1960; 
53: 739-45.
32. Cicardi M, Mannucci PM, Castelli R, et al. Reduction in transmission 
of hepatitis C after the introduction of a heat-treatment step in the 
production of C1-inhibitor concentrate. Transfusion 1995; 35: 209-
12.
33. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled 
trial to study the efficacy and safety of C1 inhibitor concentrate in 
treating hereditary angioedema. Transfusion 1998; 38: 540-9.
34. Prematta MJ, Prematta T, Craig TJ. Treatment of hereditary angio-
edema with plasma-derived C1 inhibitor. Ther Clin Risk Manag 
2008; 4: 975-82.
35. Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-deri-
ved C1 inhibitor in the treatment of hereditary angioedema. Expert 
Opin Pharmacother 2007; 8: 3173-81.
36. Bork K, Hardt J. Hereditary angioedema: long-term treatment with 
one or more injections of C1 inhibitor concentrate per week. Int 
Arch Allergy Immunol 2011; 154: 81-8.
37. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of in-
travenous C1-inhibitor therapy for hereditary angioedema and as-
sociated quality of life benefits. Eur J Dermatol 2009; 19: 147-51.
38. Longhurst H, Cicardi M, Craig T, et al. Prevention of Hereditary An-
gioedema Attacks with a Subcutaneous C1 Inhibitor. N Engl J Med 
2017; 376: 1131-40.
39. Banerji A, Busse P, Shennak M, et al. Inhibiting Plasma Kallikrein for 
Hereditary Angioedema Prophylaxis. N Engl J Med 2017; 376: 717-
28.
40. Qiu T, Chiuchiolo MJ, Whaley AS, et al. Gene Therapy for C1 Estera-
se Inhibitor Deficiency in a Murine Model of Hereditary Angioede-
ma. Allergy 2018; doi: 10.1111/all.13582.
41. http://investors.adverum.com/news-releases/news-release-details/
adverum-biotechnologies-provides-program-updates
42. Agostoni A, Cicardi M, Martignoni GC, et al. Danazol and stanozo-
lol in long-term prophylactic treatment of hereditary angioedema. 
J Allergy Clin Immunol 1980; 65: 75-9.
43. Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment 
of hereditary angioedema with attenuated androgens: a survey of 
a 13-year experience. J Allergy Clin Immunol 1991; 87: 768-73.
44. Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation 
of the liver in hereditary angioedema patients on long-term treat-
ment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 
294-8.
45. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-
term prophylaxis with attenuated androgens in hereditary angio-
edema: comparison of treated and untreated patients. J Allergy 
Clin Immunol 1997; 99: 194-6.
46. Zuraw BL, Davis DK, Castaldo AJ, Christiansen SC. Tolerability and 
Effectiveness of 17-alpha-Alkylated Androgen Therapy for Heredi-
tary Angioedema: A Re-examination. J Allergy Clin Immunol Pract 
2016; 4: 948-55 e15.
47. Agostoni A, Marasini B, Cicardi M, et al. Hepatic function and fibri-
nolysis in patients with hereditary angioedema undergoing long-
term treatment with tranexamic acid. Allergy 1978; 33: 216-21.
48. Zanichelli A, Wu MA, Andreoli A, et al. The safety of treatments for 
angioedema with hereditary C1 inhibitor deficiency. Expert Opin 
Drug Saf 2015: 1-12.
185Valerieva A i wsp. Hereditary angioedema: treatment options and availability
49. Craig T, Shapiro R, Vegh A, et al. Efficacy and safety of an intraveno-
us C1-inhibitor concentrate for long-term prophylaxis in hereditary 
angioedema. Allergy Rhinol (Providence) 2017; 8: 13-9.
50. Riedl MA, Bygum A, Lumry W, et al. Safety and Usage of C1-Inhibi-
tor in Hereditary Angioedema: Berinert Registry Data. J Allergy Clin 
Immunol Pract 2016; 4: 963-71.
51. Cancian M. Diagnostic and therapeutic management of hereditary 
angioedema due to C1-inhibitor deficiency: the Italian experience. 
Curr Opin Allergy Clin Immunol 2015; 15: 383-91.
52. Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase 
inhibitor concentrate for the treatment of hereditary angioedema. 
Immunotherapy 2014; 6: 533-51.
53. Botnaru T, Robert A, Mottillo S. Icatibant Compared to Steroids 
and Antihistamines for ACE-Inhibitor-Induced Angioedema. CJEM 
2017; 19: 159-62.
54. Caballero T, Farkas H, Bouillet L, et al. International consensus and 
practical guidelines on the gynecologic and obstetric management 
of female patients with hereditary angioedema caused by C1 inhi-
bitor deficiency. J Allergy Clin Immunol 2012; 129: 308-20.
55. Marasini B, Cicardi M, Martignoni GC, Agostoni A. Treatment of 
hereditary angioedema. Klin Wochenschr 1978; 56: 819-23.
56. Vogelaar EF, Brummelhuis HG, Krijnen HW. Contributions to the 
optimal use of human blood. 3. Large-scale preparation of human 
c1 esterase inhibitor concentrate for clinical use. Vox Sang 1974; 
26: 118-27.
57. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in 
hereditary angioedema: successful treatment of acute episodes of 
angioedema with partly purified C1 inhibitor. N Engl J Med 1980; 
302: 542-6.
58. Madaliński K, Obtułowicz K. Historia badań i organizacji leczenia 
chorych z wrodzonym obrzękiem naczynioruchowym - HAE w Pol-
sce. Alergol Immunol 2013; 10: 5-8.
59. Bozhkov B, Nikolov K, Baleva M. [Familial studies of patients with 
hereditary angioedema]. Vutr Boles 1988; 27: 62-5.
60. Longhurst H, Bygum A. The Humanistic, Societal, and Pharmaco-e-
conomic Burden of Angioedema. Clin Rev Allergy Immunol 2016; 
51: 230-9.
61. Caballero T, Aygoren-Pursun E, Bygum A, et al. The humanistic bur-
den of hereditary angioedema: results from the Burden of Illness 
Study in Europe. Allergy Asthma Proc 2014; 35: 47-53.
